Trump, pharma industry discuss boosting medicine spending abroad to cut US prices, sources say

The Trump administration is reportedly engaged in confidential discussions with pharmaceutical companies, seeking to increase drug prices in Europe and other international markets to subsequently reduce significantly higher U.S. drug costs. This strategy involves supporting drugmakers' international negotiations and leveraging trade deals, despite industry skepticism regarding European governments' willingness to pay more and expert opinions suggesting U.S. price reductions are feasible without global price hikes. This initiative represents a novel, high-stakes approach to rebalance global pharmaceutical pricing, posing potential challenges for international trade relations and industry revenue models.

Analysis

The Trump administration is pursuing a novel strategy to lower U.S. drug prices by actively collaborating with pharmaceutical companies to increase prices in foreign markets, primarily Europe. According to sources, this effort involves leveraging U.S. trade negotiations and potential tariffs to support drugmakers in their international price discussions, aiming for a "most favored nation" standard where U.S. prices match the lowest offered to other wealthy nations. This initiative is a top priority, with the White House directing trade officials to take action against countries with below-market drug prices. However, the strategy faces significant hurdles. Eli Lilly's CEO, David Ricks, noted the difficulty in convincing European governments to pay more without the use of "trade tools," and health economist Anna Kaltenboeck argues that U.S. price reductions are feasible without international hikes, as U.S. sales alone are sufficient to fund global R&D. The discussions represent a high-stakes attempt to rebalance the global pharmaceutical market, where the U.S. currently pays nearly three times more than other developed nations, but its success remains highly uncertain due to the negotiating leverage of European national healthcare systems.

Key Decisions for Investors

• Investors should closely monitor the progress of U.S. trade negotiations with the UK and EU, as these are the stated leverage points for implementing this new pharmaceutical pricing strategy.
• It is critical to assess the geographic revenue concentration of pharmaceutical holdings, as companies with heavy reliance on the U.S. market face the most significant downside pricing risk if this policy fails to lift international prices commensurately.
• Given the significant implementation uncertainty and potential for political pushback from European governments, investors should treat this as a major long-term risk factor that could introduce heightened volatility and regulatory overhang for the sector.
• The proactive engagement by firms like Eli Lilly may indicate they are attempting to shape policy, which could be a differentiating factor, but also raises their profile on a politically contentious issue.